MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma

Phase 2 Unknown 91 enrolled Xi'an Xintong Pharmaceutical Research Co.,Ltd. The First Hospital of Jilin University · collab

RandomizedSequentialOpen-labelTreatment

Summary

A randomized, open, multicenter clinical trial design was adopted, planned to be conducted in three stages, with 91 participants expected to be included in the study to evaluate the efficacy, tolerance, and safety of different doses of MB07133 in the treatment of unresectable advanced primary liver cancer.

Timeline

Start: 2020-01-17
Primary completion: 2024-06-30
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MB07133	Small molecule	600 mg/m2	Intravenous
Subject	MB07133	Small molecule	1200 mg/m2	Intravenous
Subject	MB07133	Small molecule	1800 mg/m2	Intravenous

Indications

No indication recorded.